BANK VONTOBEL/PUT/ELI LILLY & CO/640/0.1/21.06.24 | Real-time Boerse Frankfurt Warrants 05:30:32 18/06/2024 pm IST | ||
| 0.001 EUR | 0.00% |
|
| 1 month | -98.59% | ||
| 3 months | -99.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 18/24/18 | 0.001 | 0.00% |
| 17/24/17 | 0.001 | 0.00% |
| 14/24/14 | 0.001 | 0.00% |
| 13/24/13 | 0.001 | 0.00% |
| 12/24/12 | 0.001 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update June 18, 2024 at 05:30 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM8D23 |
| ISIN | DE000VM8D239 |
| Date issued | 11/01/2024 |
| Strike | 640 $ |
| Maturity | 21/06/2024 (3 Days) |
| Parity | 10 : 1 |
| Emission price | 4.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.21 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.165 € |
| Spread % | 99.40% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
885
USD
Average target price
855.4
USD
Spread / Average Target
-3.35%
- Stock Market
- Warrants
- Warrant
